Every state, kept current
The Rates plan
$29/mo7-day free trialThis page shows one representative rate per state for Q2056. Full schedules include every locality, modifier, and age-band variant.
- Every code on all 51 published schedules
- Full-schedule CSV export and state network lists
- Email alerts when a state changes its rates
$29/mo after the trial. Cancel anytime.
Publishing states
16
Median % of Medicare
--
Rate range
$5,602.43 - $588,494.80
Q2056 rates in every publishing state
| State | Medicaid rate | % of Medicare | Prior auth | Vintage |
|---|---|---|---|---|
| Arkansas | $530,100.00 | -- | -- | 2026 |
| Arizona | $587,977.76 | -- | -- | 2026 |
| California | $98,082.47 | -- | -- | 2026 |
| District of Columbia | $587,649.57 | -- | Required | 2026 |
| Idaho | $507,729.24 | -- | Required | 2026 |
| Indiana | $583,075.96 | -- | Required | 2025 |
| Kansas | $587,977.76 | -- | -- | 2026 |
| Michigan | $587,977.76 | -- | -- | 2026 |
| Mississippi | $587,649.57 | -- | -- | 2026 |
| Montana | $587,649.57 | -- | Required | 2026 |
| New Hampshire | $555,310.44 | -- | Required | 2026 |
| New Mexico | $551,318.34 | -- | -- | 2025 |
| Rhode Island | $543,851.08 | -- | -- | 2026 |
| South Carolina | $5,602.43 | -- | -- | 2026 |
| Texas | $553,378.83* | -- | -- | 2026 |
| Virginia | $588,494.80* | -- | -- | 2026 |
Published Medicaid fee-for-service schedule amounts, not a coverage or eligibility guarantee. Managed-care plan rates can differ. Where no prior-authorization flag is shown, the state does not publish one. Rows marked * are representative published variants or methodology-derived rates. "--" in the prior-auth column means the state publishes no PA flag.
Related state-specific services codes
- C1716 - Brachytherapy source, non-stranded, gold-198, per source
- C1717 - Brachytherapy source, non-stranded, high dose rate iridium-192, per source
- C1719 - Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source
- C2616 - Brachytherapy source, non-stranded, yttrium-90, per source
- C2634 - Brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source
- C2635 - Brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source
- C2636 - Brachytherapy linear source, non-stranded, palladium-103, per 1 mm
- C2638 - Brachytherapy source, stranded, iodine-125, per source
All 12 codes from Q2009 to Q2058 or every state-specific services code by number.
Frequently asked questions
How much does Medicaid pay for Q2056?
16 state Medicaid programs publish a fee-for-service rate for Q2056 (ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose), ranging from $5,602.43 in South Carolina to $588,494.80 in Virginia. The full table on this page lists every publishing state's current rate.
Which state pays the most for Q2056?
Virginia publishes the highest Medicaid rate for Q2056 at $588,494.80. South Carolina publishes the lowest at $5,602.43.
Does Q2056 require prior authorization under Medicaid?
5 of the 16 publishing states flag Q2056 as requiring prior authorization (always or conditionally) on their fee schedules. States without a flag publish no PA indicator for this code - that means "not published", not "no PA required".